TABLE 1.
Baseline group characteristics
| Healthy control | CTEPH | CTED | IPAH | PE | |
| Subjects n | 68 | 208 | 35 | 30 | 28 |
| Age years | 49 (24) | 64 (19) | 58 (27) | 64 (27) | 52 (26) |
| Female sex | 32 (47%) | 90 (43%) | 9 (26%) | 21 (70%) | 15 (54%) |
| Caucasian ethnicity | 53 (78%) | 180 (95%) | 28 (88%) | 26 (90%) | 13 (54%) |
| WHO functional class | |||||
| 1 | 4 (2%) | 6 (18%) | 5 (17%) | ||
| 2 | 42 (21%) | 17 (50%) | 4 (13%) | ||
| 3 | 151 (74%) | 11 (32%) | 21 (70%) | ||
| 4 | 7 (3%) | 0 (0%) | 0 (0%) | ||
| 6MWD m | 318 (176) | 366 (180) | 342 (244) | ||
| Pulmonary haemodynamics | |||||
| mPAP mmHg | 42 (18) | 21 (4) | 42 (17) | ||
| Cardiac index L·min−1·m−2 | 2 (0.6) | 2.4 (0.6) | 1.7 (0.8) | ||
| PVR dynes·s·cm−5 | 639 (476) | 151 (71) | 808 (642) | ||
| Clinical blood tests | |||||
| Haemoglobin g·L−1 | 140 (27) | 138 (16) | 142 (22) | ||
| Platelet count ×109 | 246 (82) | 200 (56) | 222 (77) | ||
| WCC ×109 | 7 (3) | 6.6 (2.1) | 6.9 (2.4) | ||
| Lymphocyte % | 25 (10) | 28 (13) | 18 (13) | ||
| Neutrophil % | 64 (14) | 59 (14) | 72 (14) | ||
| CRP mg·L−1 | 5 (10) | 3 (3) | 3 (4) | ||
| NT-proBNP pg·mL−1 | 592 (1576) | 113 (194) | 334 (695) | ||
| Smoking status | |||||
| Never | 91 (47%) | 16 (50%) | 15 (52%) | ||
| Ex-smoker | 87 (45%) | 13 (41%) | 11 (38%) | ||
| Current smoker | 15 (8%) | 3 (9%) | 3 (10%) | ||
| Anticoagulation medication | 137 (94%) | 15 (94%) | 30 (100%) |
Data are presented as median (interquartile range) or n (%). Percentages were calculated using the number of patients for whom data were available as the denominator. CTEPH: chronic thromboembolic pulmonary hypertension; CTED: chronic thromboembolic disease; IPAH: idiopathic pulmonary arterial hypertension; PE: pulmonary embolism; WHO: World Health Organization; 6MWD: 6-minute walk distance; mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; WCC: white cell count; CRP: C-reactive protein; NT-proBNP: N-terminal pro-brain natriuretic peptide.